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MLL1 fusions are among the most potent oncogenic drivers of leukemia development. In recent articles pub-
lished inMolecular Cell and in Cancer Cell, researchers find that MLL1 fusions are reliant on a physical inter-
action with the PAF transcription elongation complex for their recruitment to chromatin and, consequently,
leukemic transformation.Acute myeloid or lymphoid leukemias
harboring rearrangements of the MLL1
gene represent a poor-prognosis subset
of these diseases with a general unre-
sponsiveness to chemotherapy (reviewed
in Krivtsov and Armstrong, 2007). Chro-
mosomal translocations that disrupt
MLL1 generate oncogenic gene fusions
encoding the MLL1 N-terminal region
fused to one of a variety of different partner
proteins (>50 are known). A consistent
feature of otherwise diverse fusion part-
ners is the corruption of MLL1’s normal
capacity to promote self-renewal of
hematopoietic cells. The resulting MLL1
fusion undermines normal differentiation
pathways to immortalize hematopoietic
cells in an immature state. While evidence
from mouse models has established MLL1
fusions as among the most potent drivers
of leukemia known, effective strategies
have yet to be identified for neutralizing
leukemic MLL1 functions for therapeutic
benefit. One avenue toward identifying
novel therapeutic handles in these aggres-
sive leukemias is to elucidate the essential
biochemical framework of MLL1 fusionprotein complexes. Two recent articles
published in Cancer Cell and Molecular
Cell have made a pivotal advance in this
regard by identifying a specific interaction
between the PAF complex and MLL1 that
is required for leukemic transformation
(Milne et al., 2010; Muntean et al., 2010).
Hence, PAF is exposed as a conspirator
that, along with two other MLL1-associ-
ated proteins, Menin and LEDGF,
promotes leukemogenesis conferred by
MLL1 fusion proteins.
MLL1 performs its normal and leukemic
functions through involvement with active
chromatin states (Krivtsov and Armstrong,
2007). Like many other chromatin regula-
tors, MLL1 is composed of an assortment
of domains (AT hooks, CXXC, BROMO,
PHD) that can latch onto DNA or histones,
as well as a catalytic SET domain at the
C terminus that methylates histone H3
at lysine 4, a modification implicated in
active transcription (Milne et al., 2002).
MLL1 also has been shown to interact with
numerous proteins to form a higher-order
complex, e.g., Menin, LEDGF, HCF-1,
ASH2L, RbBP5, and WDR5 (Yokoyamaet al., 2004). In contrast to the full-length
molecule, the MLL1 fragment present in
leukemogenic fusions only retains the
Menin/LEDGF interaction domain, AT
hooks, and the CXXC domain, which
together are sufficient for recruitment to
target sites in the genome. Distortion of
MLL1 function is due to the replacement
of its native C-terminal effector domains
with those provided by one of many
C-terminal fusion partners. Indeed, a large
number of studies have identified protein
complexes associated with many of the
most common MLL1 fusion partners (ENL,
AF4, and AF9), all of which seem to share
a group of factors linked with regulating
transcription elongation, e.g., pTEFb and
the histone methyltransferase DOT1L
(e.g., Mueller et al., 2007). Thus, MLL1
fusions assemble a multisubunit complex
of transcriptional regulators that leads
to altered expression of MLL1’s normal
target genes, such as HOXA9.
A major mechanistic question ad-
dressed in the articles by Muntean et al.
(2010) and Milne et al. (2010) regards the
recruitment mechanism employed by the17, June 15, 2010 ª2010 Elsevier Inc. 531
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work had established the interaction
between MLL1 and Menin/LEDGF at the
extreme N terminus and the presence of
the CXXC domain as the most critical
regions of MLL1 needed for leukemic
transformation (Ayton et al., 2004).
Whereas LEDGF may promote MLL1
fusion recruitment via an affinity for chro-
matin via its PWWP domain, the MLL1
CXXC domain has a selective affinity for
unmethylated CpG DNA that could allow
MLL1 fusion occupancy at promoter
regions (Ayton et al., 2004). However, evi-
dence suggested that CpG DNA binding
alone cannot explain the requirement for
MLL1’s CXXC domain in leukemogen-
esis and that an additional unidentified
activity/interaction conferred by this
domain must be involved (Bach et al.,
2009). This prompted the authors of both
studies to examine whether a region
encompassing the CXXC domain and
flanking sequences interacts with other
proteins by immunoprecipitating this
specific fragment and identifying interact-
ing proteins by mass spectrometry. Both
studies identified the multisubunit PAF
(polymerase associated factor) complex
as an interacting partner of the extended
MLL1 CXXC region and revealed this
interaction as essential for leukemogen-
esis.
PAF was first identified as a complex
that associates with RNA polymerase II
and is composed of Paf1, Cdc73, Leo1,
Ctr9, Rtf1, and Ski8 (reviewed in
Chaudhary et al., 2007). PAF has been
implicated in a range of regulatory activi-
ties, including transcription elongation,
mRNA processing, H3K4 and H3K79
methylation, and H2B ubiquitylation.
Although no prior studies had implicated
the PAF complex in the pathogenesis of
leukemia, Cdc73 is known to function as
a tumor suppressor in parathyroid
cancers—an interesting parallel with the
MLL1-interacting protein Menin, which is
also a tumor suppressor in a host of endo-
crine cancers.
To determine the functional impact of
PAF binding by MLL1, Milne et al. (2010)
utilized published NMR structures of the
MLL1 CXXC domain to design specific
point mutations that selectively disrupted
either its DNA-binding activity or the PAF
interaction. Both mutations led to defects
in MLL1-AF9 recruitment to HOXA9532 Cancer Cell 17, June 15, 2010 ª2010 Elsin vivo, with the compound disruption of
both interactions abolishing recruitment.
The authors then introduced the same
mutant forms of MLL1-AF9 into bone
marrow cells and determined that both
DNA and PAF binding are independently
required for efficient cell immortalization.
Milne et al. (2010) also provided a mecha-
nistic explanation for the recently pub-
lished findings that wild-type MLL1 is
required for the leukemogenic activity of
MLL1 fusion proteins (Thiel et al., 2010).
They show that the third PHD domain of
MLL1, which ‘‘reads’’ H3K4me2/3 marks
on histones, is essential for recruiting
wild-type MLL1 to the HOXA9 locus. The
PHD domains, however, are missing
from the leukemogenic MLL fusion
proteins, and therefore the MLL1-AF9
fusion protein cannot be recruited to the
HOXA9 locus by itself (i.e., in the absence
of wild-type MLL1). When wild-type MLL1
is present, however, MLL1-AF9 can
occupy the HOXA9 locus. The authors
conclude that wild-type MLL1 must first
occupy the HOXA9 locus and create an
open chromatin state that subsequently
enables MLL1-AF9 to bind.
Muntean et al. (2010) likewise per-
formed a detailed deletion analysis to
identify two contact points between
sequences flanking the MLL CXXC
domain and the Paf1/Ctr9 proteins. The
authors went on to demonstrate that dis-
rupting the MLL1-PAF interaction both
via mutation and by knocking down
expression of Ctr9 or Cdc73 can inhibit
MLL1-leukemia growth by abrogating
MLL1 recruitment to Hox genes. Addition-
ally the authors noted that PAF subunit
expression is dynamically regulated
during hematopoiesis, such that PAF
might have important functions in normal
hematopoiesis in controlling stemness,
similar to what has been observed in
embryonic stem cells.
Several additional questions remain to
be answered regarding PAF’s role in
MLL1 function and the therapeutic poten-
tial of targeting this interaction. A major
issue is the relative importance of the
MLL1-PAF1 interaction for normal versus
malignant functions of MLL1. Wild-type
MLL1 is required to maintain normal
hematopoiesis, so it remains to be seen
whether MLL1 leukemias are more ‘‘ad-
dicted’’ to PAF complex function than their
normal counterparts, an issue that couldevier Inc.be addressed via conditional knockouts
of PAF subunits in mice. The two articles
also differ in their mapping of the precise
interacting sites between MLL1 and PAF
(RD1 versus RD2 region); therefore,
solving the structure of an MLL1-CXXC-
PAF complex would clarify the precise
interaction surface among these mole-
cules. Another important area of future
investigation will be to determine whether
PAF is simply a mode of recruitment for
MLL1 or whether it also participates in
chromatin modification at MLL1-bound
sites. To this end, PAF has been shown
to bind the BRE1 E3 ligase that catalyzes
H2B ubiquitylation, a histone mark known
to stimulate DOT1’s methyltransferase
activity for H3K79 (reviewed in Shilatifard,
2006). Several possibilities remain to be
examined for how precisely PAF inter-
faces with the complex regulatory mecha-
nisms employed by MLL1 fusion proteins
in leukemia.
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